Abstract: An encapsulated sunscreen product that includes a polymeric shell material having a substantially spherical geometry. The shell material is a polymeric composition that includes a photosensitizer chemically bound to the polymeric composition. The polymeric shell material has a minimum diameter of 100 nm.

Abstract: The instant disclosure relates to photosensitive capsules (sometimes referred to as “smart capsules”) and sunscreen compositions comprising the capsules that automatically adjust the Sun Protection Factor (“SPF”) of the sunscreen composition during use to provide protection against ultraviolet (“UV”) light, as needed, based on actual exposure to UV light. The photosensitive capsules comprise: (i) a polymeric photosensitive degradable shell; and (ii) one or more UV filters encapsulated by the photosensitive degradable shell, wherein the one or more UV filters is released from the photosensitive degradable shell upon exposure to UV light.

Abstract: There is described a composition comprising one or more UV filtering agents and a sunless tanning system wherein one or both of the UV filtering agent and sunless tanning system is in an encapsulated form.

Abstract: Disclosed are: a lightening composition comprising ginseng-derived exosome-like vesicles; and a method for producing the ginseng-derived exosome-like vesicles. The ginseng-derived exosome-like vesicles may have a diameter of between 20 and 500 nm, and may be isolated from ginseng root. Because the composition comprises the ginseng-derived exosome-like vesicles as an active ingredient, said composition is effective in preventing, improving or treating skin pigmentation conditions such as liver spots, freckles, lentigo, birth marks and melanoma by effectively suppressing the production of melanin.

Abstract: Products for oxidatively changing the color of keratinic fibers include at least two preparations (A) and (B), which are produced separately from one another. The first preparation (A) includes, in a cosmetic carrier, (A1) hydrogen peroxide and (A2) at least one chelating agent chosen from a group of specific chelating agents. The second preparation (B) includes, in a cosmetic carrier, (B1) at least one alkalizing agent. The preparation (A) is produced in a first container (container A). The first container includes at least two layers: an inner layer that includes a layer of a synthetic polymer (I) and an outer layer that includes a metal layer. Preparation (B) is produced in a second container (container B), which includes at least two layers: an inner layer that includes a layer of a synthetic polymer (I) and an outer layer that includes a metal layer.

Abstract: Multi-component package units (kits-of-parts), ready-to-use agents for reductive decolorizing of dyed keratinous fibers, and methods for reductive decolorizing of dyed keratinous fibers are provided herein. In an embodiment, a multi-component package unit (kit-of-parts) for reductive decolorizing of keratin fibers includes, separately packaged, a first container (A) and a second container (B). The first container (A) includes a cosmetic agent (a) and the second container (B) includes a cosmetic agent (b). Agent (a) in the first container (A) includes (a1) thiourea. Agent (b) in container (B) includes (b1) one or multiple oxidizing agents chosen from the group of hydrogen peroxide, potassium persulfate, sodium persulfate and/or ammonium persulfate.

Abstract: The present invention provides active compositions that contain an aluminum system active, a buffer comprising urea or an amino acid in free or salt form; and a calcium ion source. The compositions are stable at high pH; i.e., at a pH above 4 or 5, reaching neutral or basic pH.

Abstract: A composition containing at least 75% by weight of water, relative to the total weight of the composition, hydroxylated diphenylmethane derivative(s), oil(s) containing in its structure at least one amide unit, and crosslinked copolymer(s) containing at least one unit of an unsaturated olefinic carboxylic acid and at least one unit of a (C10-C30)alkyl ester of unsaturated carboxylic acid.

Abstract: An agent for hair deforming treatment comprising the following components (A) and (B): (A) a compound represented by the following formula (1), and (B) water: wherein R1, R2 and R3 represent H or a group represented by formula (2), and 0 to 2 thereof are H, wherein, in the formula (2), R represents H or a carboxy group, and A1 and A2 represent H, OH or a group represented by formula (3), wherein in the formula (3), any one of X, Y and X represents a site binding to the C in the formula (2), and the others represent H or —CH(OH)COOH.

Abstract: Cosmetic or dermatological composition including, in a physiologically acceptable medium, a hydrophilised extract of peppermint stems and use of such a composition as an antioxidant in a cosmetic or dermatological composition.

Abstract: The present invention relates to a composition for dyeing keratin fibres, in particular keratin fibres such as the hair, comprising: at least one oxidation base 3-(2,5-diaminophenyl)-1-propanol and/or acid salts thereof and/or solvates thereof such as hydrates; at least one particular coupler; optionally at least one fatty substance; optionally at least one basifying agent; and optionally at least one chemical oxidizing agent. The invention also relates to a process for dyeing keratin fibres such as the hair using the composition of the invention, and to a multi-compartment device for using the composition of the invention.

Abstract: An aqueous personal care composition comprising: one or more amphoacetates; one or more glutamate surfactants selected from sodium lauroyl glutamate, dipotassium cocoyl glutamate, potassium lauryl/myristoyl glutamate and combinations thereof; and cocamide MIPA; wherein the composition is free of sulfates and ethoxylates.

Abstract: Multi-component package unit (kit-of-parts), ready-to-use agent, and methods for reductive decolorizing of dyed keratinous fibers are provided herein. In an embodiment, a multi-component package unit includes, separately packaged, a first container (A), a second container (B), and a third container (C). The first container (A) includes a cosmetic agent (a) that includes (a1) one or multiple reducing agents chosen from the group of formamidine sulfinic acid, sodium dithionite, zinc dithionite, potassium dithionite, hydroxymethanesulfinic acid, aminomethanesulfinic acid, cysteine, thiolactic acid, sulphanylacetic acid (thioglycolic acid) and/or ascorbic acid. The second container (B) includes a cosmetic agent (b) that includes one or multiple oxidizing agents. The third container (C) includes a cosmetic agent (c) that includes (c1) one or multiple alkalizing agents. The weight ratio of the total amount of all reducing agents (a1) to the total amount of all oxidants (b1) has a value from about 50.0 to about 4.0.

Abstract: The subject matter of the present disclosure is an agent for the reductive decolorization of dyed keratinous fibers, more particularly human hair, containing, in a cosmetic carrier: (a) Formamidine sulfinic acid and/or salts thereof and (a) At least one compound of formula (I) Additional subjects of the present disclosure are corresponding multi-component package units and methods for reductive decolorizing of dyed keratinous fibers.

Abstract: An agent for hair deforming treatment comprising the following components (A) to (C): (A) glyoxylic acid or a hydrate or salt thereof, (B) a compound represented by the following formula (1): wherein R1 represents H or a methyl group, X represents H, OH, or a methoxy group, Y represents H, O, OH, or a methoxy group, Z represents H, an alkyl group, etc., Rx represents H, O, a methoxy group, etc., Ry represents H, OH, an aromatic hydrocarbon group, etc., and the dashed line optionally represents a double bond, and (C) water, wherein the molar ratio of the content of the component (B) to the content of the component (A), (B)/(A), is 0.01 or more and 5 or less.

Abstract: A fine emulsion-type cosmetic comprises a finely-emulsified oil phase mainly based on a silicone oil or hydrocarbon oil without use of a high-pressure emulsifying apparatus, and optionally has an average emulsion particle size of 150 nm or less comprising: an aqueous phase as a continuous layer; an oil phase dispersed in the aqueous phase and comprising 82% by mass or more of a silicone oil and a hydrocarbon oil therein; a carboxy-modified silicone represented by the following formula (1); a C16 to 22 higher alcohol; a nonionic surfactant having a POE chain and an HLB of 5 to 10; and a dihydric glycol; wherein R1 and R2 are respectively a functional group represented by —O—Si(R4)3 in which R4 is an alkyl group having 1 to 6 carbon atoms; R3 is a monovalent hydrocarbon group having 1 to 10 carbon atoms; M is a hydrogen atom, metal atom, or organic cation; A is a linear or branched alkylene group represented by CqH2q; and q is an integer of 6 to 20.

Abstract: A foundation cream/liquid with a controllable color change and a preparation method provides a pre-mixed powder for color-changeable foundation cream/liquid, including titanium dioxide and an inorganic pigment, wherein the titanium dioxide is processed with a methyl triethoxy silanization surface treatment. The inorganic pigment is processed with an octyl triethoxy silanization surface treatment. Different surface treatments are provided to the titanium dioxide and the inorganic pigment (iron oxide) in the foundation cream/liquid, such that surface properties of such two kinds of powder are quite different. A color changing effect of the color-changeable foundation cream/liquid prepared with the pre-mixed powder is controllable and rapid, a covering ability is strong; colors are varied, safety and harmlessness are guaranteed, and preparation is simple.

Abstract: Described herein are oral care compositions comprising a basic amino acid; a combination of zinc ion sources; and from about 0.75 wt. % to about 2 wt. % of a chelating system; along with methods of making and using same.

Abstract: A cosmetic or dermatologically acceptable composition is provided comprising: water; a personal care ingredient and a cationic starch characterized by: a) an amylopectin/amylose weight ratio of greater than 60/40; b) an apparent cationic molecular weight of greater than or equal to 12 million daltons; and c) a cationic degree of substitution of from 0.5 meq/g to 2.5 meq/g. Also provided are cosmetic or dermatologically acceptable compositions comprising highly substituted mung bean starches and cosmetic and dermatologically acceptable compositions which are free of polymeric silicones.

Abstract: The present invention provides topical compositions comprising a cross-linked sulfated glycosaminoglycan and methods of making and using the same for treating skin, for example for signs of skin aging or dryness.

Abstract: Provided is a concentrated emulsion and hair care compositions containing the concentrated emulsion. The emulsion comprises (a) an internal phase containing (i) a high density polyolefin with a density above 0.90 g/cm3, (ii) a low density polyolefin with a density equal to or below 0.90 g/cm3, and (iii) a cosmetically acceptable hydrocarbon oil; (b) from 0.1 to 15 wt %, based on the total weight of the emulsion, of a surfactant; and (c) balance water as a continuous phase, wherein the high and low density polyolefins have an average melt index greater than 7.

Abstract: The present invention relates to a composition, especially a cosmetic composition, for caring for and/or making up keratin fibres, and more particularly the eyelashes, comprising at least: a non-aqueous medium containing at least one hydrocarbon-based oil, particles of at least one polymer surface-stabilized with a stabilizer, the polymer of the particles being a C1-C4 alkyl (meth)acrylate polymer; the stabilizer being an isobornyl (meth)acrylate polymer chosen from isobornyl (meth)acrylate homopolymer and statistical copolymers of isobornyl (meth)acrylate and of C1-C4 alkyl (meth)acrylate present in an isobornyl (meth)acrylate/C1-C4 alkyl (meth)acrylate weight ratio of greater than 4; and a nonionic surfactant.

Abstract: The invention relates to an anhydrous liquid composition, in particular for caring for and/or making up keratinous substances, in particular the skin, comprising, preferably in a physiologically acceptable medium: a) an oily phase comprising: i) at least one non-volatile oil and ii) at least one volatile hydrocarbon oil and b) at least one monoalcohol comprising from 2 to 8 carbon atoms and c) at least one lipophilic film-forming polymer chosen from: (i) silicone resins of MQ type, (ii) silsesquioxane resins, (iii) vinyl polymers grafted with a carbosiloxane dendrimer, (iv) their mixtures, and d) at least one particulate material, the said composition comprising at least 15% by weight of non-volatile oil(s) with respect to the total weight of the composition.

Abstract: Polymers comprising at least one cationic functional group and at least one ultraviolet light-absorbing compound are disclosed herein. The resulting polymers exhibit ultraviolet light-absorbing properties and may be used in sunscreen compositions for skin and/or hair.

Abstract: Disclosed is a topical skin composition and corresponding methods for its use that includes an extract from Phaseolus vulgaris, Citris sinensis, Wedelia trilobata, Burretiodendron hsienmu, Bauhinia brachycarpa var. cavaleriei, Cystacanthus paniculatus, Caesalpinia minax, Pueraria wallichii, Tetracentron sinense, Bridelia insulana, Hedyotis verticillata, Syzygium fruticosum, Cercidiphyllum japonicum, Bauhinia glauca, Rhododendron siderophyllum, Cudrania pubescens, Cajanus cajan, Wendlandia uvariifolia, Siegesbeckia glabrescens, Azolla imbricate, Juncus bufonius, Poikilospermum suaveolens, Clerodendrum trichotomum var.

Abstract: A method of treating a fine line or wrinkle on a person's skin or increasing collagen production in skin is disclosed. The method can include topically applying to the skin a composition comprising an effective amount of an aqueous, alcoholic, or aqueous-alcoholic extract of Diospyros mespiliformis leaf to treat the fine line or wrinkle or to increase collagen production in the skin.

Abstract: The present invention relates generally to methods of use and compositions useful for treating skin to reduce the appearance of wrinkles, moisturize skin, lighten skin, reduce inflammation, increase skin firmness, and/or increase skin elasticity. The composition includes a combination of Persea gratissima (avocado) oil, Olea europaea (olive) fruit oil, and Argania spinosa kernel oil.

Abstract: Described herein are compositions useful for moisturizing and/or improving the appearance of skin by evening skin tone and/or reducing the appearance of dark spots or hyperpigmentation. The compositions comprise cosmetic ingredients such as lactobacillus ferment; Ferula foetida root extract; Helianthus annuus (sunflower) seed extract; Terminalia ferdinandiana fruit extract, and niacinamide.

Abstract: The present invention provides an impregnated porous carrier material comprising at least one active pharmaceutical ingredient (API) impregnated throughout the internal surface of a porous carrier. The present invention further provides immediate release and sustained release pharmaceutical dosage forms comprising the impregnated porous carrier material disclosed herein such that any single active pharmaceutical ingredient (API) content variability in the finished drug product has a relative standard deviation of less than 3%.

Abstract: The subject invention provides improved diclofenac gel formulations.

Abstract: Described are low viscosity, hypotonic formulations containing one or more proteins, e.g., antibodies, at high concentration, uses of the formulations, and articles of manufacture. In particular, the formulations are useful and beneficial for the subcutaneous administration or delivery of a high concentration of a protein drug, such as an antibody, to a subject who is afflicted with a disease or condition that is treatable by the protein drug.

Abstract: The invention relates to a method for contraception and for reducing menstrual problems and inducing amcnorrhca, whcrcin an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.

Abstract: The present invention relates to a sustained drug-release contact lens. More specifically, the present invention relates to a sustained drug-release contact lens including: a body having cavities configured to be recessed and spaced a predetermined distance apart from each other along a side surface thereof; a drug carried in the cavities; and a closing part closing each entrance of the cavities where the drug is carried, wherein the closing part biodegrades to open the cavities during wearing of the contact lens, and each closing part of the cavities is configured to open at a different time whereby the cavities are opened sequentially. Thus, the sustained drug-release contact lens releases a predetermined amount of the drug continuously, does not release the drug during storage as the closing parts biodegrade due to an enzyme contained in tears, and can be reloaded with the drug.

Abstract: A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-?-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.

Abstract: In one aspect the present invention features a process for making a tablet comprising the step of applying radiofrequency energy to a powder blend comprising lossy coated particles and at least one pharmaceutically active agent to sinter said powder blend into a tablet, said lossy coated particles comprising a substrate having a Q value of greater than 100 that is at least partially coated with a lossy coating comprising Hydrogenated Starch Hydrolysate.

Abstract: A particulate composition suitable for oral consumption comprising: a carrier phase which is a free flowing particulate phase comprising a poor or bitter tasting agent and a first particulate agent; and a retained phase comprising a second particulate agent, wherein the second particulate agent is or comprises a flavour agent and/or a taste-masking agent, and wherein the residence time in the mouth of the retained phase (R90: retained) is greater than the residence time in the mouth of the carrier phase (R90: carrier).

Abstract: The present disclosure relates to chewable gel products containing a gel carrier and an active pharmaceutical ingredient (API), where the chewable gel product has an acceptable taste.

Abstract: A process for the manufacture of semi-plastic pharmaceutical unit doses using a rotary moulding machine and semi-plastic pharmaceutical dosage units obtained by this process.

Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.

Abstract: The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.

Abstract: The present invention relates to: a pharmaceutical composition for preventing or treating ischemic diseases, containing liposomes into which vascular endothelial growth factor (VEGF)-derived peptides are loaded; a method for treating ischemic diseases, comprising the step of administering the pharmaceutical composition to an individual suspected of having an ischemic disease; a use of the liposomes; and a kit for evaluating, using the liposomes, the amount of liposomes, into which VEGF-derived peptides are loaded, delivered to ischemic lesions and of loaded materials released and absorbed.

Abstract: The disclosure provides pharmaceutical compositions and method of using the compositions, wherein the compositions comprise liposomes that contain two or more anticancer drugs. In various embodiments the components of the liposomes can include a) a phospholipid, b) a pegylated lipid, c) an aqueous core, and d) at least one covalently-linked drug-conjugated lipid, an encapsulated drug, or a combination thereof, wherein the drug of the lipid-drug conjugate, encapsulated drug, or both, are anticancer drugs.

Abstract: A multi-component nanoconstruct for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. The nanoparticles are linked to form the nanochain by linking first linkers and/or second linkers disposed on separate nanoparticles.

Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

Abstract: A method for preparing an itraconazole formulation including: dissolving a mixture of itraconazole and L-ascorbic acid with a mixed solvent of dichloromethane and methanol, adding a hydroxypropyl methylcellulose and a pluronic F-127 and then dichloromethane into the mixed solvent to obtain a raw material solution; feeding a carbon dioxide into a crystallization autoclave in a supercritical fluid crystallization equipment system through a pressure regulating valve; spraying the solution into the crystallization autoclave via a spray nozzle, separating out composite particles from the solution and collecting the composite particles at a bottom of the crystallization autoclave, and encapsulating the composite particles to obtain a itraconazole formulation with decreased particle size and increased bioavailability.

Abstract: The present invention provides modified release pharmaceutical compositions, and methods for administering the compositions to a user, including humans. The composition may contain a combination of ingredients in proportions calculated to achieve therapeutic effect, including at least the following ingredients: one or more natural or synthetic cannabinoids, one or more release modifying agent(s), and one or more pharmaceutically acceptable excipient(s). The composition may be in a multi-layered solid dosage form to provide fast, controlled and also sustained release of specific ingredients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. More specifically, the invention may control drug release in accordance with the therapeutic purpose and pharmacological properties of active substances.

Abstract: The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine.

Abstract: The present invention relates to pharmaceutical compositions comprising a tablet core and an immediate release coating, wherein said tablet core comprises a GLP-1 peptide and an absorption enhancer, as well as uses thereof.

Abstract: Clear bioavailable liquid softgel fill compositions comprising a) at least one analgesic and one or more of decongestants, expectorants, antitussives and/or antihistamines; b) a matrix comprising a pharmaceutically acceptable poly(alkylene glycol) and a pharmaceutically acceptable alkylene glycol; c) a solubilizing agent comprising a pharmaceutically acceptable polymeric solubilizing agent and water are disclosed. Also disclosed are methods for the preparation of such clear fill compositions, and softgel capsules containing the clear bioavailable liquid fill composition.

Abstract: Methods are for the preparation and medicinal use of pharmaceutical formulations for the treatment of bacterial infection and/or duodenal ulcer disease.